

**Supplemental Table 1:** Completeness of data contributing to the primary OCT outcome

Treatment Group	N	Baseline	Week 24	Week 48	Week 72	Week 96
Placebo	Observed	119 (97%)	119 (99%)	111 (98%)	106 (99%)	106 (97%)
	Expected	123	120	113	107	109
Ibudilast	Observed	116 (96%)	114 (97%)	106 (96%)	95 (91%)	94 (94%)
	Expected	121	117	111	104	100

Treatment Group	N	Contribute to Analysis*	Baseline <sup>†</sup>	Week 24 <sup>†</sup>	Week 48 <sup>†</sup>	Week 72 <sup>†</sup>	Week 96 <sup>†</sup>	Event Driven (Early Termination)
Placebo	123	122 (99%)	119 (97%)	119 (97%)	111 (90%)	106 (86%)	106 (86%)	3
Ibudilast	121	120 (99%)	116 (96%)	114 (94%)	106 (88%)	95 (79%)	94 (78%)	5

\*have at least one oct measurement during the study.

<sup>†</sup>Count having either the left or right side (or both).

- Subject 157-1104 (ibudilast group) had no scans collected and sent by the clinical site
- Subject 116-1143 (placebo group) had an ungradable baseline scan, with no scans collected thereafter

**Supplemental Table 2:** Data availability by instrument (Cirrus or Spectralis, expressed as number of patients):

Visit	Cirrus Machine			Spectralis Machine		
	Placebo	Ibudilast	Total	Placebo	Ibudilast	Total
Baseline	93	90	183	30	31	61
Week 24	90	86	176	30	31	61
Week 48	83	82	165	30	29	59
Week 72	78	76	154	29	28	57
Week 96	80	72	152	29	28	57